Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 99, showing 5 Applications out of 494 total, starting on record 31, ending on 35

# Protocol No Study Title Investigator(s) & Site(s)

31.

ECCT/24/05/01   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Dr Videlis Nduba
Site(s) in Kenya
1. KEMRI Centre for Clinical Respiratory Diseases Research (KEMRI CRDR)-Nairobi (Nairobi City county)
 
View

32.

ECCT/24/04/08   Gates MRI TBV02-301
    A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults.   
Principal Investigator(s)
1. Wilson Muraya
Site(s) in Kenya
1. KEMRI Mtwapa Clinical Research Site- Kilifi (Kilifi county)
 
View

33.

ECCT/24/04/07   FORMATIVE-PEARLS TRIAL
    PEARLS FORMATIVE  (Preventing pre-eclampsia: Evaluating AspiRin Low-dose regimens following risk Screening)    
Principal Investigator(s)
1. Zahida Qureshi
2. Alfred Osoti
3. George Gwako
4. Rosa Chemwey
Site(s) in Kenya
1. Kakamega General County Teaching and Referral Hospital (Kakamega county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
3. Kiambu Level 5 Hospital (Kiambu county)
4. Kisii Teaching and Referral Hospital (Kisii county)
5. Meru Teaching and Referral Hospital (Meru county)
 
View

34.

ECCT/24/04/06   REACH 2
    Realizing Effectiveness Across Continents with Hydroxyurea (REACH):  A Phase I/II Prospective Trial of Hydroxyurea for Children and Young Adults with Sickle Cell Anaemia       
Principal Investigator(s)
1. Thomas Williams
2. Russell Ware
Site(s) in Kenya
Kilifi County Referal Hospital
 
View

35.

ECCT/24/04/05   Phase III Vitiligo Study
                                                                             A Double-Arm, Open Label, Phase III Study to Compare the                                           Efficacy and Safety of SCENESSE® and Narrow-Band Ultraviolet B (NB-UVB) Light versus NB-                                                                                    UVB Light Alone in the Treatment of Vitiligo   
Principal Investigator(s)
1. Dr. Hannah Wanyika Wanyika
Site(s) in Kenya
Kenyatta National Hospital -
 
View